{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-034733","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.535860+00:00","generated_at":"2026-05-18T08:46:15.314678+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting","bullets":["Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.","Advisory say-on-pay approved, 35.4M for vs 0.9M against (95% of votes cast).","Ratified KPMG as independent auditor for FY2025, 50.8M for vs 0.2M against.","Authorized board to implement reverse stock split at ratio 1:10 to 1:40, at board's discretion (44.2M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-034733","json":"https://secwatch.observer/filing/0001628280-25-034733.json","markdown":"https://secwatch.observer/filing/0001628280-25-034733.md","text":"https://secwatch.observer/filing/0001628280-25-034733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/0001628280-25-034733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/ovid-20250710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:46:15.314678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}